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Proliferationa b s t r a c t
Peroxiredoxin 3 (Prx3) is a mitochondrial member of the antioxidant family of thioredoxin
peroxidases that uses mitochondrial thioredoxin 2 as a source of reducing equivalents to scavenge
hydrogen peroxide (H2O2). Here, we report that the protein levels of Prx3 are signiﬁcantly reduced in
VHL-deﬁcient clear cell renal cell carcinoma (CCRCC). Furthermore, stabilization of HIF-1a protein,
caused either by VHL deﬁciency under normoxia, or by hypoxia, signiﬁcantly reduced Prx3 expres-
sion. Luciferase-reporter and chromatin-immunoprecipitation assays indicated that HIF-1a binds to
the hypoxia-responsive elements of PRDX3 promoter and represses its transcription. Finally, shRNA-
based assays suggested that Prx3 downregulation is required for the HIF-1a-dependent proliferation
of CCRCC cells. Taken together, our results shed new light onto the mechanism of HIF-1a-dependent
proliferation in CCRCC cells.
 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Tumor hypoxia is one of the key factors to induce the develop-
ment of malignant tumor cells with an aggressive phenotype that
leads to rapid progression and poor prognosis [1,2]. It has been
well known that the adaptive response of cell to hypoxia is mainly
mediated by hypoxia-inducible factor (HIF)-1. HIF-1 is a heterodi-
meric transcription factor consisting of an oxygen-sensitive sub-
unit HIF-1a and a constitutively expressed subunit HIF-1b [3]. In
the normal air (normoxia), HIF-1a is hydroxylated by the PHDs.
Hydroxylated HIF-1a is ubiquitinated and targeted for proteasomal
degradation by the E3 ligase von Hippel–Lindau protein (VHL) [4].
In hypoxia, cytosolic HIF-1a is stabilized due to the inhibition of
hydroxylation and subsequently translocates into the nucleus
where it forms heterodimer with its partner HIF-1b. The HIF-1a/
HIF-1b heterodimer binds to consensus sequence 5#-RCGTG-3#
named hypoxia-responsive elements (HREs) on promoters of its
target genes such as vascular endothelial growth factor (VEGF)
and pyruvate dehydrogenase kinase 1 (PDK1) [5–8], which partic-
ipate in angiogenesis, energy metabolism, cell proliferation anddifferentiation. HIF-1 and hypoxia were also shown to contribute
to metastasis and invasion of cancers [9,10].
Peroxiredoxins (Prxs) have been shown to be involved in the
development, progression and drug resistance of cancers [11,12].
As a member of the Prx family, Prx3 contains a mitochondrial local-
ization sequence, is found exclusively in the mitochondrion, and
uses mitochondrial thioredoxin-2 as the electron donor for its per-
oxidase activity [13]. Prx3 expression is induced by oxidants in the
cardiovascular system and is thought to play a important role in
the antioxidant defense system and homeostasis within the mito-
chondria [14]. In this work, we report that PRDX3 is a direct target
gene of HIF-1a. Furthermore, the silence of PRDX3 expression by
its speciﬁc short hairpin RNA (shRNA) can restore HIF-1a-medi-
ated proliferation of CCRCC cells. These results would shed new
light for understanding mechanism for hypoxia/HIF-1a-mediated
proliferation of CCRCC cells.
2. Materials and methods
2.1. Cell culture and treatment
293T, RCC4 and RCC4/VHL were cultured in DMEM medium
(Sigma–Aldrich, MI, USA) supplemented with 10% FBS (Gibco
BRL, Gaithersburg, MD, USA). SW620 and Caki-1 were respectively
cultured in RPMI-1640 medium (Sigma–Aldrich, MI, USA) and
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5% CO2/95% air in a humidiﬁed atmosphere at 37 C. Hypoxic treat-
ment was performed in a specially designed hypoxia incubator
(Thermo Electron, Forma, MA, USA) with 1% O2, 5% CO2 and 93% N2.
2.2. Immunohistochemistry
Parafﬁn-embedded tumor tissues and normal adjacent tissues
were from Shanghai Tenth People’s Hospital. Tissue slides were
stained by antibody against Prx3 (sc-59661, Santa Cruz Biotech).
The immunohistochemical analysis was performed as previously
described [15].
2.3. qRT-PCR
Total RNA was isolated by TRIzol reagent (Invitrogen, Carlsbad,
CA) and treated with RNase-free DNase (Promega, Madison, WI).
Reverse transcription was performed with TaKaRa RNA PCR kit
(TaKaRa, Dalian, China). The double-stranded DNA dye SYBR Green
PCR Master Mixture Reagents (Applied Biosystems, Warrington,
UK) was used for quantitative real-time reverse transcription-poly-
merase chain reaction (PCR) analysis as described previously. The
following speciﬁc primers used were 50-ACGGTGTGCTGTTA-
GAAGGTTC-30 (forward) and 50-TGGACTTGGCTTGATCGTAGGA-30
(reverse) for PRDX3, and 50-CATCCTCACCCTGAAGTACCC-30 (for-
ward) and 50-AGCCTGGATAGCAAC GTACATG-30 (reverse) for Actin
as control. The folds of changes were shown as means ± S.D.’s in
three independent experiments with each triplicate.
2.4. shRNA design and transfection
Pairs of complementary oligonucleotides against PRDX3 were
synthesized, annealed and ligated into pSIREN-RetroQ according
to the manufacturer’s instruction (Clontech, Mountain View, CA).
The target sequence for PRDX3 was 50-ACCTTCTGAAAGTACTCTT-
30 and the sequences for VHL and HIF-1a have been described pre-
viously [16]. Retroviruses were produced as previously described
[10].
2.5. Western blots
Western blot was performed as described previously [16]. The
proteins were probed by antibodies against human Prx3 (sc-
59661, Santa Cruz Biotech), HIF-1a (610958, BD Transduction Lab-
oratories), VHL (NB100-1899, Novus biologicals), PDK1 (KAP-
PK112, Enzo life sciences) and Actin (JLA20, Merck).
2.6. Luciferase assay
The indicated sequences in promoter of PRDX3 were obtained
from National Center for Biotechnology Information. The promoter
sequences were ampliﬁed by PCR from genomic DNA, subcloned
into pGL3-Basic (Promega) and mutated by site-directed mutagen-
esis (Stratagene, Amsterdam, The Netherlands) in accordance with
the manufacturer’s instructions. For the luciferase assay, 293T cells
were seeded in a 12-well plate (Becton Dickinson, Franklin lakes,
NJ), and cotransfected with pEF-BOS-HIF-1a, luciferase reporter
plasmids driven by promoter fragments of PRDX3 and pRLSV40-
Renilla. After 24 h transfection, then put in normoxic or hypoxic
conditions for another 12 h. Cells were lysed and analyzed by the
Dual-Luciferase Assay system according to the manufacturer’s
instructions (Promega).
2.7. Chromatin immunoprecipitation
RCC4/VHL cells were subjected to ChIP assay as previously
described using the speciﬁc anti-human HIF-1a monoclonalantibody (BD Transduction Laboratories, Lexington, KY). PCR was
performed with the following primers targeting different regions
of human PRDX3 promoter: 50-ACACAAGGAAGGTGTGAGGT-30
(forward, P1) and 50-TCCTGACATCAGGTGATCCT-30 (reverse, P2)
and 50-AGGGATCCTGTCACAGAA-30 (forward, P3) and 50-AGACCCT-
GAGGGAGA AAT-30 (reverse, P4).
2.8. Growth curve analysis
RCC4 cells were seeded in 6-well plates (1  105 cells/well) and
allowed to attach. Transfection with shRNA was performed on the
same day and cell proliferation was examined every 24 h for
4 days. The number of viable cells were determined using Beck-
man’s automated cell counter with the trypan blue exclusion
method.
2.9. Statistical analysis
All experiments were repeated at least for three times. The Stu-
dent’s t-test was used to compare the difference between two dif-
ferent groups. P < 0.05 was considered to be statistically
signiﬁcant. The results of immunohistochemistry were analyzed
by SAS Enterprise software (SAS Institute, Cary, NC) as indicated.
3. Results
3.1. CCRCC tissues present lower expression of Prx3 that can be
regulated by VHL
With the immunohistochemical analysis of tumor tissues and
normal adjacent tissues from 30 cases of CCRCC, we showed that
there was a signiﬁcant decrease of Prx3 protein in CCRCC tissues
compared with normal tissues adjacent to cancer tissues (Fig. 1A
and B).
Because of VHL is mutated or silenced in >50% of CCRCC [17],
we asked whether the decreased Prx3 is related to VHL. RCC4
which is a VHL defective cell line derived from CCRCC and RCC4
with stable re-expression of VHL (RCC4/VHL) were tested by quan-
titative real-time PCR and western blot, respectively. The results
showed that both mRNA and protein of PRDX3 were signiﬁcantly
upregulated by VHL (Fig. 2A). Then, in order to verify the regulation
of VHL upon PRDX3, we stably transfected shRNA speciﬁcally
against VHL (shVHL) together with a scrambled shRNA into
RCC4/VHL and another renal clear cell carcinoma cell line Caki-1
in which VHL is normally expressed. Accordingly, silencing of
VHL suppressed PRDX3 expression on mRNA and protein levels
(Fig. 2B and C).
3.2. HIF-1a mediates Prx3 expression
HIF-1a is one of the most important transcription factors regu-
lated by VHL [18]. We supposed that HIF-1a might be involved in
the process that VHL regulates Prx3. Thus, we cultured RCC4/VHL
cells in normoxia and hypoxia, respectively. The results showed
that both mRNA and protein of PRDX3 were signiﬁcantly downreg-
ulated by hypoxia (1% O2) (Fig. 3A). Next, we stably transfected
shRNAs speciﬁcally against HIF-1a (a1 and a2), together with NC
into RCC4 cells. As shown in Fig. 3B, both a1 and a2 but not NC
shRNA signiﬁcantly suppressed HIF-1a and PDK1. Notably, a1
and a2 also increased Prx3 mRNA and protein. Furthermore, we
knocked down HIF-1a in Caki-1 cells, and cultured these cells in
normoxia and hypoxia for 24 h. The results showed that hypoxia
inhibited PRDX3 expression at both mRNA and protein levels,
while knockdown of HIF-1a restored it (Fig. 3C). Totally, these
results suggested that HIF-1a mediated the transcriptional sup-
pression of PRDX3 in the VHL deﬁcient CCRCC cells.
Fig. 1. CCRCC tissues present lower expression of Prx3. (A) Morphologic illustrations of representative immunohistochemical stainings of Prx3 in CCRCC tissues and normal
tissues adjacent to CCRCC. T represents tumor tissues. A represents adjacent tissues. The column represents mean with bar as S.D. of three independent experiments with
triplicate samples (⁄P < 0.05; ⁄⁄P <0.01). (B) Prx3 expression scores are shown as box plots, with the horizontal lines representing the median; the bottom and top of the boxes
representing the 25th and 75th percentiles, respectively; and the vertical bars representing the range of data. We compared CCRCC tumor tissues with matched adjacent
normal tissues (n = 30). Any outliers are marked with a circle.
Fig. 2. The expression of Prx3 is regulated by VHL. (A–C) The mRNA and protein levels of the indicated genes were respectively detected by real-time quantitative RT-PCR and
Western blot. RCC4/VHL and Caki-1 cells were infected with retroviral vectors harboring shRNAs against VHL (shVHL) or scrambled negative control (NC) (B and C). EV
represents empty vector. The column represents mean with bar as S.D. of three independent experiments with triplicate samples (⁄P < 0.05; ⁄⁄P < 0.01).
Fig. 3. Prx3 is negatively regulated by HIF-1a. The mRNA and protein levels of the indicated genes were respectively detected by real-time quantitative RT-PCR and Western
blot. (A) RCC4/VHL cells were exposed to normal air or hypoxia (1% O2) for 12 h. (B) RCC4 cells were stably transfected with shRNAs against HIF-1a (a1and a2). (C) Caki-1
cells transfected with shRNAs against HIF-1a (a1 and a2) were incubated in normoxia or hypoxia for 12 h. Columns, means of three determinations; bars, S.D. (⁄P < 0.05;
⁄⁄P < 0.01).
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PRDX3 are required for HIF-1a-driven Prx3 expression
Bioinformatic analysis did show four potential HREs within 2 kb
regions upstream the transcriptional start site of PRDX3 (Fig. 4A).
Then, we subcloned the DNA fragment carrying these four poten-
tial HREs into a luciferase report vector pGL3-basic (upper panel,
Fig. 4A), which was transfected together with Renilla as theinternal control into 293T cell line for the convenience of transfec-
tion. Twelve hours later, these cells were treated under normoxia
or hypoxia for additional 24 h. The results revealed that hypoxia
dramatically decreased the luciferase activity (lower panel,
Fig. 4A). By the way, the ectopic expression of HIF-1a protein also
inhibited the luciferase activity in a dose-dependent manner
(Fig. 4B). These data suggested that the fragment of PRDX3 pro-
moter does respond to HIF-1a protein. Thereafter, we tried to
Fig. 4. Two HREs in promoter of PRDX3 are essential for HIF-1a transactivity. (A) 293T cells were transfected with luciferase reporter plasmids driven by four putative HREs
in PRDX3 promoter, which are shown on the top and middle panels, and were grown in the normal air or hypoxia for 12 h. In top diagram of putative HREs (black ovals),
empty circles represent the transcriptional start point of PRDX3. (B) 293T cells were transfected with luciferase reporter plasmids driven by four putative HREs in PRDX3
promoter together with the indicated doses of HIF-1a and grown in the normal air for 36 h. Protein levels of HIF-1a were detected by western blot with Actin as a loading
control (low panel). (C) Luciferase reporter plasmids driven by the HREs or CG/AA mutated HRE sequences as indicated were transfected together with HIF-1a expressing
vector or empty vector into 293T cells for 36 h in normal air. All the relative luciferase activities of PRDX3 promoter were normalized by pSV40-Renilla and estimated as the
relative folds against cells under normal air (A, lower panel) or empty vector-transfected cells (B and C). (D) RCC4/VHL cells were grown under normoxia and hypoxia for 12 h.
Chromatin immunoprecipitation assay was performed as described in Section 2. The column represents mean with bar as S.D. of three independent experiments with
triplicate samples (⁄P < 0.05; ⁄⁄P < 0.01).
Fig. 5. The proliferation of CCRCC regulated by HIF-1a is induced by the suppression of Prx3 expression. (A, C, E) Growth curves of indicated cells. (n = 3; ⁄⁄P < 0.01; Student’s
t-test). (B) RCC4 a1 cells were transfected with NC or shRNA against PRDX3 (shPRDX3). Protein levels of Prx3 were analyzed by western blot with Actin as a loading control.
(D) RCC4 NC or RCC4 a1 cells were transfected with shRNA against PRDX3 (shPRDX3). The indicated proteins were detected by western blot.
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expression. For this purpose, luciferase reporter plasmids driven by
PRDX3 promoter containing mutation (CG/AA) of HREs as indicated(Fig. 4C) were transfected into 293T cells together with HIF-1a
expressing plasmid. As shown in Fig. 4C, mutation (CG/AA) of
HRE3 or HRE4 signiﬁcantly increased their activities. These data
3394 H. Xi et al. / FEBS Letters 588 (2014) 3390–3394proposed that two HREs between 1497 and 1375 bp (HRE3 and
HRE4) in the promoter of PRDX3 are required for HIF-1-driven low
expression of Prx3.
This conclusion could be consolidated by chromatin immuno-
precipitation assay in hypoxia-incubated 293T cells. As shown in
Fig. 4D, anti-HIF-1a antibody but not normal IgG could precipitate
HREs at 1497 to 1375 bp (HRE3 and HRE4) but not HRE4 at
179 to 175 bp (HRE1).
3.4. Prx3 mediates the HIF-1a-induced proliferation of CCRCC cells
To understand the potential role of HIF-1a mediated Prx3
expression in CCRCC progression, our results showed that RCC4
stably transfected with shRNA speciﬁcally against HIF-1a (a1)
remarkably decreased cell proliferation compared with the control
cells (Fig. 5A). We speculated that Prx3 upregulation by knock-
down of HIF-1a might play a role in HIF-1a-induced proliferation.
When we stably transfected shRNAs speciﬁcally against PRDX3
together with NC into RCC4 a1 cells (Fig. 5B), the growth curve
showed that the knockdown of PRDX3 could rescue cell prolifera-
tion in RCC4 a1 cells (Fig. 5C). Moreover, we silenced the expres-
sion of PRDX3 in both RCC4 NC and corresponding RCC4 a1 cells
(Fig. 5D). When stably transfected with shRNA speciﬁcally against
PRDX3, there were no signiﬁcant differences on the proliferation
rates between RCC4 NC and corresponding RCC4 a1 cells
(Fig. 5E). These results supported that Prx3 mediated the HIF-1a-
induced proliferation of CCRCC cells.
4. Discussion
In this study we showed for the ﬁrst time that Prx3 is robustly
downregulated in CCRCC, for which HIF-1a is responsible. Next, we
identiﬁed HIF-1a as a transcription factor for PRDX3 gene. The
main role of HIF-1a is transcriptional activation of its target genes.
But it can also function as a transcriptional repressor. It can repress
some target genes such as SOD2, PPARa and Bax through transcrip-
tion inactivation [16,19,20]. Our result that HIF-1a inhibits PRDX3
expression provides new clue on the role of HIF-1a as a transcrip-
tional repressor.
The expression of HIF-1a in CCRCC is higher than normal tissues
because VHL is mutated or silenced in more than 50% of CCRCC
[17]. HIF-1a is a master regulator for proliferation of cancer cells
and endows cancer cells the advantage of growth [1]. Our results
support that CCRCC cell lines and tissues present lower expression
of Prx3 and Prx3 mediates the HIF-1a-induced proliferation of
CCRCC cells. Prx3 is an important cellular antioxidant that regu-
lates physiological levels of H2O2. ROS acts not only as a damaging
oxidant but also a signaling molecule [21]. ROS signaling is
involved in some crucial biologic processes such as cell prolifera-
tion and differentiation [22–24]. One possible reason as we specu-
lated is that the down-regulation of Prx3 maintains a proper level
of ROS for the prosperous proliferation of CCRCC cells. In the future,
it is of great interest for us to explore whether Prx3 is involved in
other cellular activities driven by HIF-1a or whether Prx3 endows
HIF-1a with new functions.
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